Bicycle Therapeutics - BCYC Stock Forecast, Price & News

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCYC shares.
View BCYC analyst ratings or view top-rated stocks.

14 Wall Street analysts have issued 12-month price targets for Bicycle Therapeutics' stock. Their BCYC share price forecasts range from $30.00 to $80.00. On average, they anticipate the company's share price to reach $55.58 in the next twelve months. This suggests a possible upside of 147.9% from the stock's current price.
View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts.

Bicycle Therapeutics' stock was trading at $60.87 at the start of the year. Since then, BCYC stock has decreased by 63.2% and is now trading at $22.42.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our BCYC earnings forecast.

Bicycle Therapeutics plc (NASDAQ:BCYC) released its quarterly earnings results on Thursday, August, 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by $0.05. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 30.07% and a negative net margin of 533.03%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC).

(BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Bicycle Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (4.87%), Samlyn Capital LLC (3.51%), SV Health Investors LLC (3.06%), Candriam S.C.A. (2.82%), FMR LLC (2.39%) and First Light Asset Management LLC (2.37%). Insiders that own company stock include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends.

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCYC stock can currently be purchased for approximately $22.42.

Bicycle Therapeutics (NASDAQ:BCYC) has a market capitalization of $665.34 million and generates $11.70 million in revenue each year. The company earns $-66,820,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis.

The company employs 119 workers across the globe.

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The official website for the company is www.bicycletherapeutics.com. The company can be reached via phone at 441223261503.